durogesic dtrans 75 micrograms/hour transdermal patch
imbat limited - fentanyl - transdermal patch - 75 micrograms/hour - phenylpiperidine derivatives; fentanyl
durogesic dtrans 25 micrograms/hour transdermal patch
imbat limited - fentanyl - transdermal patch - 25 micrograms/hour - phenylpiperidine derivatives; fentanyl
durogesic dtrans 100 micrograms/hour transdermal patch
imbat limited - fentanyl - transdermal patch - 100 micrograms/hour - phenylpiperidine derivatives; fentanyl
durogesic dtrans 100 micrograms/hour transdermal patch
janssen sciences ireland uc - fentanyl - transdermal patch - 100 micrograms/hour - phenylpiperidine derivatives; fentanyl
durogesic dtrans 12 micrograms/hour transdermal patch
janssen sciences ireland uc - fentanyl - transdermal patch - 12 micrograms/hour - phenylpiperidine derivatives; fentanyl
durogesic dtrans 25 micrograms/hour transdermal patch
janssen sciences ireland uc - fentanyl - transdermal patch - 25 micrograms/hour - phenylpiperidine derivatives; fentanyl
durogesic dtrans 50 micrograms/hour transdermal patch
janssen sciences ireland uc - fentanyl - transdermal patch - 50 micrograms/hour - phenylpiperidine derivatives; fentanyl
durogesic dtrans 75 micrograms/hour transdermal patch
janssen sciences ireland uc - fentanyl - transdermal patch - 75 micrograms/hour - phenylpiperidine derivatives; fentanyl
fentanyl sandoz
sandoz new zealand limited - fentanyl 16.8mg; - transdermal patch - 100 mcg/h - active: fentanyl 16.8mg excipient: durotak 87-4287 pegoterate - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.
fentanyl sandoz
sandoz new zealand limited - fentanyl 2.1mg; - transdermal patch - 12 mcg/h - active: fentanyl 2.1mg excipient: durotak 87-4287 pegoterate - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.